Summit Therapeutics Inc. (NASDAQ:SMMT)’s traded shares stood at 2.48 million during the last session, with the company’s beta value hitting -0.97. At the close of trading, the stock’s price was $1.64, to imply a decrease of -5.75% or -$0.1 in intraday trading. The SMMT share’s 52-week high remains $5.78, putting it -252.44% down since that peak but still an impressive 59.76% since price per share fell to its 52-week low of $0.66. The company has a valuation of $345.83M, with an average of 4.73 million shares in intraday trading volume over the past 10 days and average of 4.22 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Hold for Summit Therapeutics Inc. (SMMT), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give SMMT a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Summit Therapeutics Inc. (NASDAQ:SMMT) trade information
After registering a -5.75% downside in the last session, Summit Therapeutics Inc. (SMMT) has traded red over the past five days. The stock hit a weekly high of 1.7600 this Wednesday, 03/15/23, dropping -5.75% in its intraday price action. The 5-day price performance for the stock is 7.89%, and -20.77% over 30 days. With these gigs, the year-to-date price performance is -61.41%. Short interest in Summit Therapeutics Inc. (NASDAQ:SMMT) saw shorts transact 3.91 million shares and set a 0.47 days time to cover.
Analysts on Wall Street suggest a consensus price target of $4.00, implying an increase of 59.0% to the stock’s current value. The extremes give us $4.00 and $4.00 for target low and target high price respectively. As such, SMMT has been trading -143.9% off suggested target high and -143.9% from its likely low.
Summit Therapeutics Inc. (SMMT) estimates and forecasts
The rating firms project that company’s revenue will shrink -92.30% compared to the previous financial year.
Earnings reports from the last fiscal year show that sales brought in $4.55 million and $192k respectively in the corresponding quarters.
SMMT Dividends
Summit Therapeutics Inc. has its next earnings report out between May 09 and May 15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Summit Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Summit Therapeutics Inc. (NASDAQ:SMMT)’s Major holders
Summit Therapeutics Inc. insiders hold 82.66% of total outstanding shares, with institutional holders owning 1.59% of the shares at 9.20% float percentage. In total, 1.59% institutions holds shares in the company, led by Vanguard Group, Inc. (The). As of Sep 29, 2022, the company held over 0.78 million shares (or 0.39% of shares), all amounting to roughly $0.92 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 0.42 million shares, or about 0.21% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $0.5 million.
We also have Vanguard Total Stock Market Index Fund and iShares NASDAQ Biotechnology ETF as the top two Mutual Funds with the largest holdings of the Summit Therapeutics Inc. (SMMT) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 0.73 million shares. This is just over 0.36% of the total shares, with a market valuation of $0.87 million. Data from the same date shows that the other fund manager holds a little less at 0.23 million, or 0.11% of the shares, all valued at about 0.96 million.
